A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent

Inclusion Criteria:

• Active RA according to the revised (1987) ACR criteria or EULAR/ACR (2010) criteria

• Participants who have an inadequate response to current non-biologic DMARD therapy orthe first anti-TNF agent (in monotherapy or in combination with MTX or othernon-biologic DMARDs). Inadequate response to anti-TNF treatment is defined as DAS28score improvement of less than 1.2 or participants achieving a DAS28 score improvementof 1.2 but not achieving low disease activity (current DAS28-ESR above 3.2) accordingto a treat-to-target strategy and have not been previously exposed to treatment withtocilizumab. Inadequate response to non-biologic DMARD therapy will be assessedaccording to local guidelines and the participants will need to be eligible forbiologic therapy according to local guidelines

• Oral corticosteroids (≤10 mg/day prednisone or equivalent) and non-steroidalanti-inflammatory drugs (NSAIDs; up to recommended dose) are permitted if on stabledose regimen for greater than or equal to [≥] 4 weeks prior to baseline

• Permitted non-biologic DMARDs are allowed if on stable dose for at least 4 weeks priorto baseline

• Receiving treatment on an outpatient basis, not including tocilizumab

• Females of childbearing potential and males with female partners of childbearingpotential must agree to use reliable means of contraception as defined by protocolduring the study and for at least 3 months following the last dose of tocilizumab

Exclusion Criteria:

• Major surgery (including joint surgery) within 8 weeks prior to screening or plannedmajor surgery within 6 months following baseline

• Rheumatic autoimmune disease other than RA

• Functional Class IV as defined by the ACR Classification of Functional Status inRheumatoid Arthritis

• Diagnosis of juvenile idiopathic arthritis or juvenile RA and/or RA before the age of 16

• Prior history of or current inflammatory joint disease other than RA

• Exposure to tocilizumab either intravenous or SC at any time prior to baseline

• Treatment with any investigational agent within 4 weeks (or 5 half-lives of theinvestigational drug, whichever is longer) of screening

• Intra-articular or parenteral corticosteroids within 4 weeks prior to baseline

• History of severe allergic or anaphylactic reactions to human, humanized or murinemonoclonal antibodies

• Known active current or history of recurrent infections

• Major episode of infection requiring hospitalization or treatment with IV antibioticswithin 4 weeks of screening or oral antibiotics within 2 weeks of screening

• Active tuberculosis (TB) requiring treatment within the previous 3 years

• Positive for hepatitis B or hepatitis C virus infection

• Primary or secondary immunodeficiency (history of or currently active)

• Pregnant or lactating women

• Inadequate hematologic, renal or liver function